Header_Image_Investors
Corporate Profile

Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer therapeutics, the Company is developing next-generation tyrosine kinase inhibitors (TKIs): “pan-variant” targeted therapies that address all major drug resistant mutations. Theseus believes a pan-variant approach is the most effective way to address cancer resistance.

The Company’s lead program, THE-630, is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor to address C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Corporate Presentation
Stock Price
NASDAQTHRX
Recent News Releases from Theseus
Jan 10, 2022

Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and...

Dec 16, 2021

Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative...

Nov 15, 2021

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of...

View All

Recent Events
Tuesday, November 16, 2021 - Friday, November 19, 2021

Pre-record available beginning Thursday, November 18th at 8:00am GMT / 3:00am ET and available through Friday, November 19th at 5:00pm GMT / 12:00pm ET

View all